ReviewExpert review of proteomics2019
Recent advances in the metabolomic study of bladder cancer.
Review in Expert review of proteomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Unmasking the Metabolite Signature of Bladder Cancer: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.Analytical and bioanalytical chemistry · 2026Article
- Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer.Cancer & metabolism · 2026Article
- Metabolic Profiling Reveals Insights Into Bladder Cancer Pathogenesis and Recurrence.Advances in urology · 2026Article
- Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer.The Journal of pathology · 2025Article
- Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility.BioMedicine · 2025Review
- Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping.Research square · 2024Article
- Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layeredFrontiers in oncology · 2024Article
- Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.Cancer & metabolism · 2023Article
- Clinicopathological and prognostic significance of Ephrin A3 in bladder urothelial carcinoma.Oncology letters · 2023Article
- Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.Cancer immunology, immunotherapy : CII · 2023Review
- Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma andFrontiers in immunology · 2023Article
- Data Processing and Analysis in Liquid Chromatography-Mass Spectrometry-Based Targeted Metabolomics.Methods in molecular biology (Clifton, N.J.) · 2023Article
- A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients.Metabolites · 2022Article
- Review
- Article
- Surface-Enhanced Raman Spectroscopy of Pretreated Plasma Samples Predicts Disease Recurrence in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy.International journal of nanomedicine · 2022Article
- Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?Metabolites · 2021Review
- Current Development and Application of Anaerobic Glycolytic Enzymes in Urothelial Cancer.International journal of molecular sciences · 2021Review
- Multiple Chromatographic Analysis of Urine in the Detection of Bladder Cancer.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionMetabolomics is a chemical process, involving the characterization of metabolites and cellular metabolism. Recent studies indicate that numerous metabolic pathways are altered in bladder cancer (BLCA), providing potential targets for improved detection and possible therapeutic intervention. We review recent advances in metabolomics related to BLCA and identify various metabolites that may serve as potential biomarkers for BLCA. Areas covered: In this review, we describe the latest advances in defining the BLCA metabolome and discuss the possible clinical utility of metabolic alterations in BLCA tissues, serum, and urine. In addition, we focus on the metabolic alterations associated with tobacco smoke and racial disparity in BLCA. Expert commentary: Metabolomics is a powerful tool which can shed new light on BLCA development and behavior. Key metabolites may serve as possible markers of BLCA. However, prospective validation will be needed to incorporate these markers into clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.